Efficacy and safety of tadalafil in the treatment of Latin American men with erectile dysfunction: Results of integrated analyses

Journal of Sexual Medicine

Volumn 5, Issue 8, 2008, Pages 1965-1976

  Rubio aurioles, Eusebio ^a   Casabé, Adolfo ^b   Torres, Luiz O ^c   Quinzaños, Luis ^d   Glina, Sidney ^e   Filimon, Ioana ^f   Kopernicky, Vladimir ^f   Leñero, Enrique ^f  

^a Asociacion Mexicana para la Salud Sexual AC   (Mexico)

^b The Middlesex Hospital   (Argentina)

^c Clinica de Urologia e Andrologia Belo Horizonte   (Brazil)

^d HOSPITAL ÁNGELES DEL PEDREGAL   (Mexico)

^e HOSPITAL IPIRANGA   (Brazil)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

Efficacy; Erectile Dysfunction; Erectile Function; Ethnicity; Latin American; Safety; Tadalafil

Indexed keywords

PLACEBO; TADALAFIL;

ADULT; AGED; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ERECTILE DYSFUNCTION; GASTRITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PENIS ERECTION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEXUAL INTERCOURSE; SOUTH AND CENTRAL AMERICA; STOMACH HEMORRHAGE; TREATMENT DURATION; URINARY TRACT INFECTION; VISUAL FIELD DEFECT;

EID: 48749091835     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2008.00860.x     Document Type: Article

References (18)

1. Torres LO, Ugarte y Romano F, Glina S, eds. Reporters and participants of the 1st Latin American Erectile Dysfunction Consensus Meeting. 1st Latin American Erectile Dysfunction Consensus. Chapter 1. Erectile Dysfunction epidemiology. Int J Impot Res 2003; 15 (7 suppl): S2-4.
2. Chen KK, Jiann BP, Lin JS, Lee SS, Huang ST, Wang CJ, Hsieh JT, Su CK, Costigan TM, Emmick JT. Efficacy and safety of on-demand oral tadalafil in the treatment of men with erectile dysfunction in Taiwan: A randomized, double-blind, parallel, placebo-controlled clinical study. J Sex Med 2004; 1: 201-8.
3. Rodríguez Vela L, LledóGarcía E, Rajmil O, Mo D, Cassinello A, Casariego J. Preferencia de tadalafilo vs. sildenafilo en pacientes espaÑoles con disfunción eréctil: Resultados procedentes de un estudio multicéntrico internacional. Actas Urol Esp 2006; 30: 67-79.
4. Morillo LE, Díaz J, Estevez E, Costa A, Méndez H, Dávila H, Medero N, Rodriguez N, Chaves M, Vinueza R, Ortiz JA, Glasser DB. Prevalence of erectile dysfunction in Colombia, Ecuador, and Venezuela: A population-based study (DENSA). Int J Impot Res 2002; 14 (2 suppl): S10-8.
5. Ugarte y Romano F, Barroso Aguirre J. Prevalencia de disfunción eréctil en México y factores de riesgo asociados. Rev Mex Urol 2001; 61: 63-76.
6. Laumann EO, West S, Glasser D, Carson C, Rosen R, Kang J. Prevalence and correlates of erectile dysfunction by race and ethnicity among men aged 40 or older in the United States: From the male attitudes regarding sexual health survey. J Sex Med 2007; 4: 57-65.
7. Brock GB, Mcmahon CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin G, Whitaker S. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses. J Urol 2002; 168: 1332-36.
8. Lue TF. Erectile disfunction. N Engl J Med 2000; 342: 1802-13.
9. Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am 2005; 32: 379-95.
10. Carrier S, Brock GB, Pommerville PJ, Shin J, Anglin G, Whitaker S, Beasley CM Jr. Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: A randomized, double-blind, parallel, placebo-controlled clinical trial. J Sex Med 2005; 2: 685-98.
11. Juilfs DM, Soderling S, Burns F, Beavo JA. Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs). Rev Physiol Biochem Pharmacol 1999; 135: 67-104.
12. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the international index of erectile function. Urology 1999; 54: 346-51.
13. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30.
14. Gomery P, Bullock A, McGettigan J, Munarriz R, Natanegara F, Hague J, Kuepfer C, Abuja S, Wong D. Tadalafil is efficacious in Black American and Hispanic men with erectile dysfunction: Results from multiple observations in men with erectile dysfunction in national tadalafil study in the US (MOMENTUS). Int J Impot Res 2007; 9: 76-83.
15. McMahon CN, Smith CJ, Shabsighm R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ 2006; 332: 589-92.
16. Guay AT. Optimizing response to phosphodiesterase therapy: Impact of risk-factor management. J Androl 2003; 24 (6 suppl): S59-62.
17. Carson CC, Rajfer J, Eardley I, Carrier S, Denne JS, Walker DJ, Shen W, Cordell WH. The efficacy and safety of tadalafil: An update. BJU Int 2004; 93: 1276-81.
18. Marumo K, Imaoka T, Fujimoto K, Watts S, Stothard D, McGill J. A comparison of the efficacy and tolerability of tadalafil 10mg and 20mg in Japanese patients with severe erectile dysfunction. J Sex Med 2007; 4: 745-52.